全球克隆氏症治療市場規模、佔有率、趨勢和成長分析報告（2026-2034）

克隆氏症治療市場預計將從 2025 年的 183.8 億美元成長到 2034 年的 245.4 億美元，2026 年至 2034 年的複合年成長率為 3.26%。

隨著發炎性腸道疾病（IBD）在全球範圍內的日益流行，克隆氏症治療藥物的全球市場正經歷著穩定成長。克隆氏症是一種慢性疾病，會導致胃腸道炎症，需要長期藥物治療。人們對胃腸道疾病的認知不斷提高，以及診斷技術的進步，都促進了對有效治療方法的需求成長。

該市場的主要驅動力之一是先進生物製藥和標靶治療方法的進步。製藥公司正致力於開發能夠減輕發炎並改善患者生活品質的創新藥物。此外，醫療保健成本的上升和獲得專業醫療服務的機會增加也是推動先進治療方法的重要因素。

未來幾年，隨著免疫學研究與開發以及生物製藥研發的不斷進步，克隆氏症治療市場預計將迎來強勁成長。包括生物相似藥和個人化治療方案在內的新治療方法的引入，有望改善治療效果。患者意識的提高和醫療基礎設施的改善也將進一步推動全球市場的擴張。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球克隆氏症治療市場：按類型分類

• 市場分析、洞察與預測
• 非手術治療（抗發炎藥、免疫抑制劑、抗生素等）
• 手術治療

第5章：全球克隆氏症治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 注射藥物
• 口服

第6章：全球克隆氏症治療市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球克隆氏症治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • AbbVie Inc
  • Perrigo Company Plc
  • Pfizer Inc
  • Johnson & Johnson Services Inc
  • Ferring BV
  • Bristol-Myers Squibb Company（Celgene Corporation）
  • F. Hoffmann-La Roche Ltd（Genentech Inc.）
  • UCB SA
  • Salix Pharmaceuticals
  • Gilead Sciences Inc

The Crohn's Disease Treatment Market size is expected to reach USD 24.54 Billion in 2034 from USD 18.38 Billion (2025) growing at a CAGR of 3.26% during 2026-2034.

The global Crohn's disease treatment market is experiencing steady growth due to the increasing prevalence of inflammatory bowel diseases (IBD) worldwide. Crohn's disease is a chronic condition that causes inflammation in the digestive tract and requires long-term medical management. Growing awareness about gastrointestinal disorders and improved diagnostic techniques are contributing to the rising demand for effective treatment options.

One of the major drivers of this market is the increasing development of advanced biologic therapies and targeted treatment approaches. Pharmaceutical companies are focusing on developing innovative drugs that can reduce inflammation and improve patient quality of life. Additionally, rising healthcare expenditure and better access to specialized healthcare services are supporting the adoption of advanced treatment options.

In the coming years, the Crohn's disease treatment market is expected to witness strong growth as research in immunology and biologic drug development continues to advance. The introduction of novel therapies, including biosimilars and personalized treatment approaches, is likely to improve treatment outcomes. Increasing patient awareness and improved healthcare infrastructure will further contribute to the expansion of this market globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Non-SurgicalA (Anti-Inflammatory, Immune System Suppressors, Antibiotics, Others)
• Surgical

By Route of Administration

• Injectable
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Takeda Pharmaceutical Company Limited, , AbbVie Inc, Perrigo Company plc, Pfizer Inc, Johnson Johnson Services Inc, Ferring BV, BristolMyers Squibb Company Celgene Corporation, F HoffmannLa Roche Ltd Genentech Inc, UCB SA, Salix Pharmaceuticals, Gilead Sciences Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CROHN'S DISEASE TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Non-Surgical (Anti-Inflammatory, Immune System Suppressors, Antibiotics, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Surgical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CROHN'S DISEASE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CROHN'S DISEASE TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CROHN'S DISEASE TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CROHN'S DISEASE TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 AbbVie Inc
  • 9.2.2 Perrigo Company Plc
  • 9.2.3 Pfizer Inc
  • 9.2.4 Johnson & Johnson Services Inc
  • 9.2.5 Ferring B.V
  • 9.2.6 Bristol-Myers Squibb Company (Celgene Corporation)
  • 9.2.7 F. Hoffmann-La Roche Ltd (Genentech Inc.)
  • 9.2.8 UCB S.A
  • 9.2.9 Salix Pharmaceuticals
  • 9.2.10 Gilead Sciences Inc